RxDoctor Payments Data

Kevin Williams, MD

Internal Medicine · Peckville, PANPI 1750361168

Payments from drug & device makers

$620in general payments, 2019–2025

Across 45 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$76
  • Novo Nordisk$70
  • GSK$64
  • Johnson & Johnson$56
  • Novartis$46
  • Sanofi-aventis U.S. LLC$46
  • plus $263 from 10 others

What the payments were for

  • Food & beverage$620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$620 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,949
Medicare patients
216
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$105,015
EliquisApixaban101$90,673
JanuviaSitagliptin Phosphate77$71,532
TradjentaLinagliptin42$28,684
MounjaroTirzepatide26$27,927
JardianceEmpagliflozin34$24,988
XareltoRivaroxaban33$22,785
FarxigaDapagliflozin Propanediol21$20,281
TrulicityDulaglutide15$18,240
EntrestoSacubitril/Valsartan17$17,769
JanumetSitagliptin Phos/Metformin Hcl15$11,271
Breo ElliptaFluticasone/Vilanterol17$9,176
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$8,595
Spiriva RespimatTiotropium Bromide11$6,645
MyrbetriqMirabegron14$6,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$105,01574 claims
PfizerEliquis, Paxlovid$76$94,961120 claims
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Stiolto Respimat$43$65,27798 claims
Lilly USA, LLCMounjaro, Trulicity$12$46,16641 claims
Johnson & JohnsonXarelto$56$22,78533 claims
AstraZenecaFarxiga$33$20,28121 claims
NovartisEntresto$46$17,76917 claims
GSKBreo Ellipta$64$9,17617 claims
Astellas Pharma US IncMyrbetriq$20$6,12214 claims
AbbVieSynthroid$41$1,94342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Peckville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →